Intellia Therapeutics (NTLA) Capital Expenditures (2015 - 2025)

Intellia Therapeutics (NTLA) has 11 years of Capital Expenditures data on file, last reported at $126000.0 in Q4 2025.

• On a quarterly basis, Capital Expenditures fell 37.93% year-over-year to $126000.0 in Q4 2025; TTM through Mar 2026 was $1.0 million, a 156.69% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, up 95.67% from the prior year.
• Capital Expenditures for Q4 2025 stood at $126000.0, down from $1.0 million in the prior quarter.
• Over the last five years, Capital Expenditures for NTLA reached as high as $4.6 million in Q2 2023 and fell as low as -$10.9 million in Q4 2023.
• Historically, Capital Expenditures has averaged $880500.0 across 5 years, with a median of $552000.0 in 2021.
• On a YoY basis, Capital Expenditures climbed as much as 15789.66% in 2023 and fell as far as 1864.09% in 2023.
• Year by year, Capital Expenditures stood at $2.9 million in 2021, then sank by 119.42% to -$557000.0 in 2022, then tumbled by 1864.09% to -$10.9 million in 2023, then surged by 101.86% to $203000.0 in 2024, then tumbled by 37.93% to $126000.0 in 2025.
• Per Business Quant data, the three most recent Capital Expenditures figures were $126000.0 in Q4 2025, $1.0 million in Q3 2025, and -$82000.0 in Q2 2025.